Here are the 8-K filings from Unity Biotechnology Inc (UNBX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow UNBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UNBX filings page.
Unity Biotechnology, Inc. submitted a Certificate of Dissolution for the company that is effective September 26, 2025, and executed a Lease Termination Agreement and Amendment with Bayside Area Development, LLC dated September 24, 2025. The filing also references an interactive XBRL cover page and is signed by Craig Jalbert, President. These actions indicate formal steps to dissolve the corporate entity and to end at least one lease arrangement in late September 2025.
The document contains core corporate-closeout actions but no financial statements, forward guidance, or details about creditor claims, asset transfers, or shareholder distributions. There is insufficient transactional or financial detail in this filing to assess impacts on creditors, investors, or ongoing contractual obligations beyond the cited lease termination and the effective dissolution date.
Unity Biotechnology, Inc. held a special stockholder meeting where investors approved a proposal authorizing a potential corporate dissolution and an adjournment proposal related to that meeting. The voting power present represented 600,944,604 votes, or 97.36% of the outstanding voting power entitled to vote.
Stockholders approved the Dissolution Proposal by 450,228,768 votes for and 150,685,568 against, with 30,268 abstentions. A separate Adjournment Proposal was also approved. The Board now has discretion to determine the timing of filing a Certificate of Dissolution, to proceed with, amend, or abandon the dissolution under Delaware law.
The company warns that trading in its securities is highly speculative and risky, and that trading prices may bear little or no relationship to any value ultimately realized by security holders.